The Most Important Unanswered Question in Health-Tech Right Now

Across payers, providers, employers, and investors, three priorities are rising to the top entering 2026:

1️⃣ Cost-trajectory impact

2️⃣ Workflow simplicity

3️⃣ Decision-grade evidence

Every organization is tightening standards.

But here’s the surprising part:

There’s still no agreement on which of these actually matters most.

And that disagreement is shaping how deals get evaluated, delayed, or approved.

If clinical outcomes are strong but cost movement isn’t clear…

➡️ Is the solution contract-ready?

If economics are compelling but workflow adds friction…

➡️ Does it scale across clinicians or sites?

If attribution is sound but the evidence isn’t explainable across teams…

➡️ Does it survive procurement review?

If ROI is solid but adoption is inconsistent…

➡️ Does it clear renewal?

These aren’t edge cases—they’re becoming the core decision points for 2026.

So here’s the real question for the ecosystem:

👉 What do you believe will matter most in 2026—outcomes, economics, or workflow?

And why?

Perspectives vary dramatically across clinical teams, operators, payers, and investors.

I’m genuinely interested in how different leaders see it.

Tom

Founder & Commercialization Architect | Axis Growth Partners

Recent Posts